PeerCurrent.com|Stay current with the people and research shaping what comes next.

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Researcher

Sean C. Dougherty

University of Virginia

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials Reviews Guidelines

Latest

Everything in the corpus, newest first.

AUG 8, 2026 · JOURNAL ARTICLE

Association of SGLT2 Inhibitor Use with Clinical Outcomes in Patients Receiving Immune Checkpoint Inhibitors: A Pan-Tumor Propensity-Matched Analysis

The Oncologist

Retrospective propensity-matched cohort study showing modest survival improvement (HR 0.68) with SGLT2i+ICI versus ICI alone, but limited by observational design, immortal time bias concerns, and lack of mechanistic validation.

PromisingQingyi He Asal Pilehvari Diabetes Treatment and Management

Reported

Median overall survival (SGLT2i+I…27.4 months

Median overall survival (ICI alon…17.4 months

Hazard ratio0.68

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support